Drug Profile
Lenacapavir - Gilead Sciences
Alternative Names: GS 6207; GS-6207-02; GS-714207; GS-HIV; GS-HIV Na; Lenacapavir sodium; SunlencaLatest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Acetamides; Alkynes; Antiretrovirals; Antivirals; Chlorobenzenes; Fluorinated hydrocarbons; Pyrazoles; Pyridines; Sulfonamides; Sulfones
- Mechanism of Action Capsid protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered HIV-1 infections
Most Recent Events
- 05 Mar 2024 Efficacy and adverse event data from phase Ib trial in HIV-1-infections released by Gilead Sciences
- 05 Mar 2024 Efficacy and adverse event data from the phase II/III ARTISTRY-1 trial in HIV-1 infections released by Gilead Sciences
- 03 Mar 2024 Efficacy and adverse events data from a phase II trial in HIV-1 infections released by Gilead Sciences at the 31st Conference on Retroviruses and Opportunistic Infections 2024 (CROI-2024)